Outcome statement - September 2022 DUSC meeting

PBAC

3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available.

The DUSC reviewed the utilisation of the following PBS listed medicines:

  • Atezolizumab for patients with small cell lung cancer
  • Durvalumab for patients with non-small-cell lung cancer
  • Nivolumab for patients with malignant melanoma

Read DUSC outcome statement


Michael Wonder

Posted by:

Michael Wonder